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Long-term safety and outcome of a temporary
self-expanding metallic stent for achalasia:
a prospective study with a 13-year
single-center experience
Abstract To prospectively evaluate
the long-term clinical safety and
efficacy of a newly designed self-
expanding metallic stent (SEMS) in
the treatment of patients with
achalasia. Seventy-five patients with
achalasia were treated with a
temporary SEMS with a 30-mm
diameter. The SEMSs were placed
under fluoroscopic guidance and
removed by gastroscopy 4–5 days
after stent placement. Follow-up data
focused on dysphagia score, technique
and clinical success, clinical remis-
sions and failures, and complications
and was performed at 6 months,
1 year, and within 3 to 5 years, 5 to
8 years, 8 to 10 years, and >10 years
postoperatively. Stent placement was
technically successful in all patients.
Complications included stent
migration (n=4, 5.33%), chest pain
(n=28, 38.7%), reflux (n=15, 20%),
and bleeding (n=9, 12%). No
perforation or 30-day mortality
occurred. Clinical success was
achieved in all patients 1 month after
stent removal. The overall remission
rates at 6 months, 1, 1–3, 3–5, 5–8,
8–10, and >10 year follow-up
periods were 100%, 96%, 93.9%,
90.9%, 100%, 100%, and 83.3%,
respectively. Stent treatment failed
in six patients, and the overall
remission rate in our series was 92%.
The median and mean primary
patencies were 2.8±0.28 years (95%
CI: 2.25–3.35) and 4.28±0.40 years
(95% CI: 3.51–5.05), respectively.
The use of temporary SEMSs with
30-mm diameter proved to be a
safe and effective approach for
managing achalasia with a
long-term satisfactory clinical
remission rate.
Keywords Achalasia . Self-
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Introduction
Pneumatic dilation (PD) is considered the first-line therapy
for esophageal achalasia in many institutions [1–11] since
remission can be achieved in 60 to 90% of the patients [12,
13]. However, this therapeutic strategy remains controver-
sial since long-term remission rates after PD have been
reported to drop progressively with time, from 20% to 61%
at 10 years [2, 4, 7, 8, 10, 14], especially in young subjects
[10], leading some authors to consider surgery as an
alternative option.
Self-expanding metallic stents (SEMS) have been the
most common form of palliative treatment of patients with
malignant esophageal dysphagia and/or esophagorespira-
tory fistulas for the last 2 decades [15–20]. However, the
use of esophageal stents in benign esophageal conditions
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Shanghai, Chinahas been considered to be relatively contraindicated
because of concerns about an increased risk of complica-
tions, such as stent migration, reflux, perforation, bleeding,
and, most importantly, new strictures caused by stent-
induced tissue hyperplasia [21–27].
Recently,thistraditionalviewhasbeguntochange,anda
number of case reports or small series of data presentations
have suggested the feasibility of stent placement in the
cardiac esophagus [28–33]. Since July 1994, we have used
the placement of a new, specially designed self-expandable
metallic stent (Youyan Yijin Advanced Materials Co., Ltd.,
Beijing, China) in the distal esophagus. The purpose of this
study was to prospectively evaluate the long-term clinical
safety and efficacy of a newly designed SEMS with a
30-mm diameter in the treatment of patients with esopha-
geal achalasia.
Materials and methods
Study design
This pilot study was approved by the Institutional Review
Board at The Sixth Affiliated People’s Hospital of
Shanghai Jiao Tong University, and informed consent
was obtained from each patient. From July 1994 to
December 2007, we performed a prospective study of
fluoroscopical placement of a SEMS in patients with
primary esophageal achalasia. The inclusion criteria for
stent placement were as follows: (1) documented primary
esophageal achalasia; (2) recurrent dysphagia following
pneumatic balloon dilation; (3) patient life expectancy of
more than 6 months. The exclusion criteria were (1) a
lesion longer than 6 cm; (2) presence of dysfunction of
blood coagulation, active infection, significant cardiac or
pulmonary disease, malignancy, and significant psycho-
logical or psychosocial dysfunction; (3) World Health
Organization (WHO) performance score ≥3. The preoper-
ative diagnosis was based on clinical presentation, barium
swallow, gastroscopy, or esophageal manometry. These
procedures were performed by an interventional radiologist
(Y.S.C.) who had 15 years of experience in gastrointestinal
interventional radiology.
Patients were evaluated before and immediately after
stent placement, at 3 months, 6 months, and then every
6 months after stent removal until death. The evaluations
before placement of the metal stent were performed by
three radiologists participating in the study. Postoperative
regular follow-up was performed by responses to a
standardized questionnaire for symptoms by telephone
or outpatient clinic interview, barium swallow, and, if
necessary, endoscopy. Parameters evaluated during follow-
up included: (1) WHO performance status (0 = normal
activity, 1 = symptoms but ambulatory, 2 = in bed less than
50% of time, 3 = in bed more than 50% of time, and
4=100% bedridden); (2) dysphagia score (grade 0, no
dysphagia; grade 1, some solid food; grade 2, can swallow
liquids only; grade 3, difficulty with liquids and saliva;
grade 4, complete dysphagia); (3) outcomes (technical and
clinical success, 30-day mortality, clinical remission or
failures, dysphagia score and WHO performance status,
survival, and cause of death); (4) complications and
recurrent dysphagia; (5) specific symptoms, such as
substernal pain, heartburn, regurgitation, and fever. All
evaluation items were recorded in a case record form.
Prospective data collection focused on dysphagia score,
technical and clinical outcome, clinical remission or
failures, and specific symptoms.
Stent construction and insertion procedure
The self-expandable metallic stent was woven from a
single thread of 0.16-mm highly elastic nitinol wire with a
good histocompatibility and memory. On the one hand, the
stent could expand to its expected and maximal diameter at
body temperature; on the other hand, the stent could shrink
and become soft at cold temperatures. The stent had a
tubular configuration as shown in Fig. 1. The body of the
stent covered with polyethylene was 30 mm in diameter
and 60–80 mm in length when fully expanded. Three
radiopaque markers made of gold wire attached at both
ends and in the middle of the body part facilitated precise
placement of the stent. The stents were constructed by a
manufacturer (Youyan Yijin) according to our specifica-
tions. For implantation under fluoroscopic guidance, the
stent was mounted in a compressed state on the guiding
tube by the introducer sheath 24 Fr (8 mm) in diameter.
The self-expandable metallic stent was developed by
both our institute and the Youyan Yijin Advanced
Materials Cooperation (Youyan Yijin). It was specifically
designed for placement of the stent in the esophageal
cardia. Topical anesthesia of the pharynx using an aerosol
spray was routinely performed before the procedure, and
sedative drugs were not used. Details of the stent placement
Fig. 1 Photograph of a partially
covered self-expandable
metallic stent (60 mm × 30 mm)
1974techniques are provided elsewhere [28, 29]. In brief,
prior to the procedure, a water-soluble contrast swallow
(Ultravist 300; Schering, GuangZhou, China) was used to
indicate the proximal and distal borders of the esophageal
achalasia. After topical anesthesia (lidocaine 2%), a
0.035-inch guide wire (Radiofocus M; Terumo, Tokyo,
Japan) with a straight 5-Fr catheter (Torcon NB; Cook,
Bloomington, IN) was advanced perorally until the tip
reached the gastric body and then exchanged for a stiffer
one (0.035-inch Amplatz super-stiff). A 24-Fr delivery
system (Youyan Yijin) was inserted over the guide wire
until the proximal and distal edges of the stent bridged the
esophageal achalasia under fluoroscopic control, and the
stent was then deployed by pulling back the introducer
sheath. Correct placement of the stent and satisfactory
achalasia coverage were confirmed by contrast-enhanced
fluoroscopy with peroral administration of water-soluble
contrast (Ultravist) after deploying the stent. Patients ate
semisolid food on the day after stent placement and were
given prophylactic H2 receptor blockade to prevent reflux
esophagitis.
Retrieval of the stent was performed with the help of a
gastroscopy 3–7 days after stent placement. First, 500–
1,000 ml of ice-cold water was injected via the bioptic hole
to retract the stent, and then the stent was grasped by the
retrieval lasso or the proximal stent wire and gently pulled
out. Usually less than 10 min was required for this
procedure. Gastroscopy and esophageal radiography were
performedimmediately after removalofthestenttoruleout
possible complications, such as bleeding, perforation, etc.
Postoperative outcome evaluation
Technical success wasdefined as successful insertion of the
stent into the esophageal achalasia without any major
complications, such as esophageal rupture or massive
bleeding. Clinical success was defined as the symptomatic
improvement in dysphagia and good esophageal emptying
on esophagography 1 month after removal of the stent.
Primary patency was defined as the time interval from stent
remove to clinical failure without subsequent stent place-
ment or balloon dilation.
Complications, including esophageal perforation, chest
pain, and reflux, were evaluated. Esophageal perforation
was defined as contrast leakage from the esophageal lumen
on immediate esophagography or pneumomediastinum or
pneumoperitoneum on immediate chest radiograph. Severe
painwasdefinedaspainthatdevelopedafterstentplacement
requiring narcotic analgesics. Gasotroesophageal reflux was
defined as contrast reflux through the gasotroesophageal
junction, as confirmed by follow-up esophagography.
All patients were followed up as outpatients for a mean
of 4.01±3.18 years (range: 0.5–11.8 years). Outcome
assessment was performed at 6 months, 1 year, and within
3 to 5 years, 5 to 8 years, 8 to 10 years, and >10 years
postoperatively. The clinical follow-up evaluation was
focused on dysphagia, regurgitation, heartburn, and sub-
sternal pain. The incidence of each symptom was graded
according to the proposal by Johnson and De Meester [34]
as follows: grade 0, absence of the symptom; grade 1,
occasional episodes of the symptom reported to occur less
than once weekly; grade 2, frequent episodes of the
symptom reported to occur more than once weekly; grade
3, persisting daily symptoms. To estimate the effectiveness
of treatment, the following grading system was used: A
score of 0 to 2 was considered excellent, 3 to 5 was
considered good, 6 to 8 was considered fair, and 9 to 12
was considered poor. Excellent/good results were con-
sidered as clinical remission, whereas fair/poor results were
clinical failures. Patients with poor results were candidates
for subsequent balloon dilation or stent placement.
Statistical analysis
Allthe data were expressedas the mean ± SD.Comparisons
of pre- and postprocedure dysphagia score between the two
groupswere performedbyapplyingthe Mann-Whitneytest.
The curve of primary patency was calculated according to
the Kaplan-Meier method. Statistical analyses were per-
formed using SPSS statistical software (version 13.0 for
Windows, SPSS Inc., Chicago, IL). A p value < 0.05 was
considered significant.
Results
Demographics
The characteristics of the patient population in this study
are summarized in Table 1. A total of 75 patients who
underwent stent placement for achalasia during the 13-year
study period were enrolled in the analysis. These included
36 men and 39 women with a mean age of 36.36±
12.33 years (range: 12–72 years). The mean time interval
between a significant dysphagia confirmation and stent
placement was 5.23±3.49 years (ranging from 1.1–
14.6 years). Current symptoms were dysphagia (n=75,
100%), chest pain (n=47, 71%), regurgitation (n=37,
23%), and heartburn (n=28, 23%), with a mean weight loss
of 3.42±3.07 kg (range: 0.3–12.6 kg). The mean dysphagia
score before stent placement was 2.8±0.52. The mean
diameter of the narrowest region of the cardia was 5.98±
2.18 mm with a mean length of 19.24±6.45 mm.
Technical and initial clinical outcome
Fluoroscopic stent placement in the distal esophagus was
technically successful in all patients without procedure-
related complications. Initially, all patients required the
1975placement of only one stent to cover the length of the
esophageal achalagia. Complete expansion of the placed
stent occurred within 24 h after stent placement. No patient
underwent balloon dilatation, either before or after stent
placement. The mean time of the procedure was 19±6 min
(range, 10–30 min).
Stent migration occurred in four (5.33%) patients, and
all of them needed a second stent placement 2–4 days after
stent placement. Twenty-eight (38.7%) patients com-
plained of chest pain within 5 days after stent placement,
in which two required analgesics for severe pain. Reflux
and bleeding (after stent removal) were observed in 15
(20%) and 9 (12%) patient, respectively, both of which
were alleviated or disappeared spontaneously following
stent removal without additional treatment. No perforation
or food impaction occurred in our series after stent
placement, and there was no 30-day mortality.
The clinical symptoms of dysphagia resolved in all
patients, and all patients were able to swallow satis-
factorily within 24 h after successful stent placement.
The average time from SEMS placement to stent removal
was 4 to 5 days. Clinical success was achieved in all
patients with patency of the distal esophagus 1 month
after stent removal, and the dysphagia score significantly
improved for all patients, with a median score of 2.8±
0.52 before stent placement to a median score of 0.19±
0.39 (P<0.001).
Long-term follow-up and final outcome
The long-term follow-up and clinical outcome following
stent treatment at different follow-up time points are
s h o w ni nT a b l e1. The mean time from stent removal
to last follow-up assessment was 4.01±3.18 years
(range: 0.5–11.8 years). All patients were followed up
and assessed at 6 months and 1 year, 66 were assessed
for 1–3y e a r s ,3 3w e r ea s s e s s e df o r3 –5y e a r s ,2 4
were assessed for 5–8 years, 13 were assessed for 8–
10 years, and 6 were assessed for more than 10 years,
prospectively.
Follow-up evaluation at 3 months and 1 year
postoperatively
At 6 months postoperatively, the mean dysphagia score
of 0.23±0.38 decreased significantly compared with the
mean preoperative value 2.8±0.52 (P<0.001). The mean
dysphagia score at the 1-year postoperative follow-up
evaluation was 0.25±0.45 with an overall excellent and
good successe rate of 96%. None of the patients exhibited
dysphagia relapse during a 6-month follow-up, and 3
patients out of 75 exhibited dysphagia relapse during a 6–
12-month follow-up.
Long-term follow-up evaluation
The overall mean symptom score at the 1−,3 −,5 −,8 −, and
>10-year follow-up remained significantly lower than the
preoperative values. The cumulative clinical remission
rates at 1–3, 3–5, 5–8, 8–10, and >10 years after stent
removal for achalasia were 93.9%, 90.9%, 100%, 100%,
and 83.3%, respectively (Figs. 2 and 3).
Within the 13-year follow-up period, stent treatment was
considered to have failed in six patients after a median
follow-up period of 3.18±3.83 years (range 0.6–
10.4 years), and the overall cumulative success rate in
our series was 92%. Four patients continued to be followed
up due to mild recurrent dysphagia, and the remaining two
decided to undergo Heller myotomy and were excluded
from this study. None of the patients died at the end of this
report.
Cessation of primary patency occurred in six patients as
a result of recurrence. The median and mean primary
patency was 2.8±0.28 years (95% CI: 2.25–3.35) and
4.28±0.40 years (95% CI: 3.51–5.05), respectively.
Discussion
Treatment of achalasia with the use of SEMS, originally
used as a last resort in patients who had failed medical
Table 1 The long-term follow-up and clinical outcome following stent treatment at different follow-up time points
Follow-up No. of patients Clinical remission Clinical failure
Excellent Good % Fair Poor %
6 months 75 72 3 100
1 year 75 70 2 96 3 4
1–3 years 66 36 26 93.9 4 6.1
3–5 years 33 19 11 90.9 2 1 9.1
5–8 years 24 2 22 100
8–10 years 13 2 11 100
>10 years 6 5 83.3 1 16.7
1976therapy or pneumatic dilation, or who were poor surgical
candidates, was first described by De Palma in 1998 with
encouraging results [33]. To date, only a few reports in the
English literature describe treating achalasia with the use of
SEMS [23, 27, 32, 33]. Although the management of
benign esophageal strictures with stent placement is
becoming better established, some authors do not recom-
mend using EMS in achalasia because of poor results and
complications [23, 27, 32]. However, we believe that
temporary SEMSs are helpful in the treatment of achalasia
[28–31]. These long-term results suggest that treatment of
achalasia with the use of SEMS is safe and feasible.
The new large-sized, temporary SEMS has two unique
advantages over the conventional, permanent, small-sized
stent and pneumatic dilatation: (1) it provides long-term
good clinical symptomatic remission of dysphagia with
one session of stent placement; (2) it maximally decreases
the risk of complications, such as stent migration, perfo-
ration, and new strictures caused by stent-induced tissue
hyperplasia.
In this uncontrolled prospective study of 75 patients with
achalasia, the newly designed SEMS placement was
technically successful in all of the patients, with a post-
procedural clinical success rate of 100%. There was no
procedure-related mortality and perforation in this study,
and all complications were temporary and could be
managed without surgical intervention. The SEMS place-
ment led to a 96% clinical remission rate at 1-year follow-
up. Over the >5-year and >-10-year follow-up periods, the
clinical remission remained high and effective in 100% and
83.3% of patients, respectively. Our data showed a longer
term remission rate than did the results of other published
studies with repeated pneumatic dilatations [1–14]. The
long-term follow-up results showed that this new stent
design provided excellent/good symptomatic relief of
achalasia in most of the patients (Fig. 2). To date, there
have been no randomized and prospective clinical trials
examining the utility of SEMS placement in the treatment
of patients with achalasia. This study was the largest series
of SEMS placements reported for managing patients with
achalasia; it addressed the role of SEMS in patients with
achalasia and demonstrated the long-term safety and
effectiveness of temporary SEMS placement as an
alternative approach for achalasia. The results were also
much better than the previous reports of treating achalasia
with the use of SEMS [23, 27, 32, 33]. The difference lies
Fig. 2 Erect fluoroscopic im-
ages in a 42-year-old woman
with primary achalasia. (a)
Antero-posterior esophagogram
before stent placement shows a
smooth tapered beak-like
appearance (arrow) at the level
of the gastroesophageal junction
with significant esophageal
barium retention. (b) A 30-mm
diameter stent was placed at the
gastroesophageal junction with
successful dilation of the lower
esophageal segment, and an
antero-posterior esophagogram
immediately after stent place-
ment confirms complete esoph-
ageal emptying with symptom
relief. (c) Left anterior oblique
esophagogram after removal of
the stent demonstrates signifi-
cant improved contrast passage
through the widened lumen
(arrow) at the level of the
gastroesophageal junction with
complete improvement of her
symptoms. (d) Right anterior
oblique esophagogram 5 years
after stent removal displays
improved contrast passage
through the gastroesophageal
junction with relief of the
symptoms. (e) Lateral esopha-
gogram 10 years after stent
removal shows improvement of
esophageal barium emptying
with no residual symptoms
1977in the fact that the stent we used was a temporary SEMS
with a 30-mm diameter and not the commonly used
permanent, small-sized stent.
Stent migration was the the most frequent complication
for stents placed for benign strictures, ranging from 18.7%-
81.8% [23–25, 35]. Although different types of esophageal
SEMS have been used, these stents were of comparatively
small diameter and limited radial force, attributes that may
have contributed to the more frequent occurrence of
migration. In this study, the lower migration rate (5.3%,
4/75) may seem to contribute to the effectiveness of large-
sized temporary SMES. The suggested mechanism for
stent migration in our series was thought to be prevented by
the great radial expansile force and friction between the
uncovered nitinol wire tube and the esophageal wall. We
were able to demonstrate that the stent was resistant to
migration in 71 of 75 (94.7%) patients, which indicated
that the stent design specialized for cardiac application has
exerted great influence on preventing stent migration and
might have helped to minimize the likelihood of migration.
However, the large-sized SEMS with great radial force may
result in another serious complication—perforation.
Perforation is a serious complication found in 1% and
5% of patients with pneumatic dilation in a large series [2]
anda systematic review[36],andthe incidence will be high
with the increase of the balloon diameter (>30 mm) [1]. In
this study, we observed no incidents of esophageal
perforation during stent placement. The main reason may
be attributed to the characteristic of the SEMS. The stent
expanded to its full size within 24 h after placement, and
the radial expansile force was generated spontaneously,
slowly, and evenly during stent expansion. Thus, the
tearing of the cardiac musculature by the stent was slow
and gentle, and not like the pneumatic dilation, which can
cause acute and sudden tears. The spontaneous, slowly and
evenly generated radial expansile force ensured the safety
of stent placement and maximally decreased the risk of
perforation. As for new strictures induced by the long-term
stent placement as mentioned above [23, 27, 32, 33], there
was little likelihood of tissue hyperplasia in our series due
to short-term stent placement.
Although the incidence of stent migration, perforation,
and new strictures was decreased with the use of the large-
sized temporary stent, the concomitant complications
following stent placement, such as chest pain (38.7%,
28/75), gastro-esophageal reflux (20%, 15/75), and bleed-
ing (12%, 9/75), were a little higher than those following
pneumatic dilatation [2–11, 36], perhaps because of the
radial force and expansion of the stent. These complica-
tions were temporary and were alleviated or disappeared
spontaneously after removal of the stent, and without
additional treatment in most of the cases. As for the
possible mechanism for temporary stent placement, we
considered that it mainly was attributed to slow tearing of
the cardia muscularis with stent expansion. Generally, at
body temperature, the stent would gradually expand to the
expected diameter within 24 h, and the cardia muscularis
was torn slowly and regularly with relatively few scars
during stent expansion. Therefore, the incidence of reste-
nosis was very low when it was repaired [31].
This study, however, had a few limitations. This was a
single-center studywith no control studies.Therefore, future
randomized trials comparing our stent and pneumatic dilata-
tion are needed to compare the efficacy, risk of complica-
tions, and recurrent dysphagia, with particular attention
given to perforation, reflux, stent migration, and long-term
clinical efficacy. We only used subjective criteria to assess
the long-term clinical remission or failure after stent treat-
ment in this study; some better scientific assessment, such as
esophageal manometry, PH value of the lower esophageal
Fig. 3 Curves of clinical
remission rate changing over
time during 13-year follow-up
1978sphincter, or timed barium esophagram, should be added to
more precisely evaluate the long-term clinical outcomes.
In conclusion, despite some temporary complications
concomitant with stent placement, our long-term results
demonstrate that the newly designed temporary SEMS with
a 30-mm diameter was a safe and effective device for
treating clinical symptomatic remission of esophageal
achalasia. The large-sized temporary SEMS may be an
important tool for reducing the risk of complications, such
as stent migration, perforation, and new strictures, and it
ensured a long-term duration of efficacy, which may justify
the use of self-expanding metal stents in benign esophageal
achalasia and serve as an alternative or complementary
method to pneumatic dilatation.
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